Differentiating Attributes of Our Programs

• Novel mechanisms offering potential as first-in-class medications
• First available therapy and/or substantial improvement over existing therapies for serious diseases
• Targeted mechanisms of action with the potential for a favorable benefit-risk profile
• Candidates for accelerated clinical development and regulatory pathways
• Identified biomarkers and/or published clinical proof of concept increase the probability of regulatory approval
• Associated biomarkers offer the potential for better patient identification and higher response rates